Treatment persistence in attention deficit/hyperactivity disorder: A retrospective analysis of patients initiated on lisdexamfetamine vs other medications

Journal of Medical Economics

Volumn 16, Issue 11, 2013, Pages 1275-1289

  Setyawan, Juliana ^a   Guérin, Annie ^b   Hodgkins, Paul ^a   Gauthier, Geneviève ^b   Cloutier, Martin ^b   Wu, Eric ^b   Haim Erder, M ^a  

^a SHIRE   (United States)

^b ANALYSIS GROUP   (United States)

Author keywords

ADHD; Attention deficit hyperactivity disorder; Discontinuation; Non stimulant; Stimulant; Treatment persistence

Indexed keywords

AMPHETAMINE PLUS DEXAMPHETAMINE; ATOMOXETINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; LISDEXAMFETAMINE; METHYLPHENIDATE;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD;

ADOLESCENT; ADULT; AGE FACTORS; AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; COMORBIDITY; DEXTROAMPHETAMINE; DRUG COMBINATIONS; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MEDICATION ADHERENCE; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84886387867     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.839947     Document Type: Article

References (33)

1. Verma R, Balhara YP, Mathur S. Management of attention-deficit hyperactivity disorder. J Pediatr Neurosci 2011;6:13-18
2. Danckaerts M, Sonuga-Barke EJ, Banaschewski T, et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry 2010;19:83-105
3. Geissler J, Lesch KP. A lifetime of attention-deficit/hyperactivity disorder: diagnostic challenges, treatment and neurobiological mechanisms. Expert Rev Neurother 2011;11:1467-84
4. National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder-Diagnosis and management of ADHD in children, young people and adults-NICE clinical guideline 72. 2009. Available at: http://www.nice.org.uk/nicemedia/live/12061/42059/42059.pdf
5. MTA Cooperative Group. Multimodal treatment study of children with ADHD. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1073-86
6. Spencer, TJ. ADHD treatment across the life cycle. J Clin Psychiatry 2004;65:22-6
7. Group Health. Attention Deficit Hyperactivity Disorder (ADHD): Adults-Diagnosis and Treatment Guideline. 2011. Available at: https://www.ghc.org/all-sites/guidelines/adhd-adult.pdf
8. Shaw M, Hodgkins P, Cad H, et al. A systematic review and analysis of long-term outcomes in ADHD: effects of treatment and non-treatment. BMC Med 2012;10:99
9. Cascade E, Kalali AH, Weisler RH, et al. Seasonality and the changing adult/child prescription ratios in ADHD Therapy. Psychiatry (Edgmont) 2008;5:23-5
10. Canadian ADHD Practice Guidelines (CAP Guidelines). 3rd edn. 2010. Available at: http://www.caddra.ca/cms4/pdfs/caddraGuidelines2011.pdf
11. Murray-Close D, Hoza B, Hinshaw S, et al. Developmental processes in peer problems of children with ADHD in the MTA Study: developmental cascades and vicious cycles. Dev Psychopathol 2010;22:785-802
12. McCarthy S, Asherson P, Coghill D, et al. Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry 2009;194:273-7
13. Sobanski E, Sabljic D, Aim B, et al. Driving performance in adults with ADHD: results from a randomized, waiting list controlled trial with atomoxetine. Eur Psychiatry 2013;28:379-85.
14. Jerome L, Segal A, Habinski L. What we know about ADHD and driving risk: a literature review, meta-analysis and critique. J Can Acad Child Adolesc Psychiatry 2006;15:105-25
15. Barner J, Khoza S, Oladapo A. ADHD medication use, adherence, persistence and cost among Texas Medicaid children. Curr Med Res Opin 2011;27(2 Suppl):13-22
16. Christensen L, Sasane R, Hodgkins P, et al. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin 2010;26:977-89
17. Wong IC, Asherson P, Bilbow A, et al. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)-a pharmacoepidemiological and qualitative study. Health Technol Assess 2009;13:iii-iv, ix-xi, 1-120
18. Perring C. Medicating children: the case of ritalin. Bioethics 1997;11:228-40
19. Brinkman W, Epstein J. Treatment planning for children with attention-deficit/hyperactivity disorder: treatment utilization and family preferences. Patient Prefer Adherence 2011;5:45-56
20. Van den Ban E, Souverein PC, Hanna Swaab H, et al. Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands. ADHD Atten Def Hyp Disord 2010;2:213-20
21. van de Loo-Neus G, Rommelse N, Buitelaar J. To stop or not to stop? How long should medication treatment of attention-deficit hyperactivity disorder be extended? Eur Neuropsychopharmacol 2011;21:584-99
22. Kaplan G, Newcorn J. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. Pediatr Clin N Am 2011;58:99-120
23. Setyawan J, Hodgkins P, Guerin A, et al. Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis: a retrospective analysis J Med Econ 2013;16:962-75
24. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
25. Elixhauser A, Steiner C, Kruzikas D. Comorbidity software documentation. HCUP Methods Series Report # 2004-1. ONLINE February 6, 2004. US Agency for Healthcare Research and Quality; 2004. http://www.hcupu-s.ahrq.gov/ toolssoftware/comorbidity/comorbidity.jsp. [Accessed 12 Sep 2013]
26. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition [DSM-IV]. APA; 1994. Washington doi:10.1176/appi.books.9780890423349.7060
27. Marcus SC, Wan GJ, Kemner JE, et al. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2005;159:572-8
28. Winterstein AG, Gerhard T, Shuster J, et al. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother 2008;42:24-31
29. Centers for Medicare & Medicaid Services; Medicaid by Population. Medicaid website. http://www.medicaid.gov/Medicaid-CHIP-Program-lnformation/By- Population/By-Population.html. Accessed March 2013
30. Bones RK, Perez K, Rodriguez-Sanz M, et al. Prevalence of mental health problems and their association with socioeconomic, work and health variables: findings from the Spain National Health Survey. Psicothema 2010;22:389-95
31. Davis E, Sawyer MG, Lo SK, et al. Socioeconomic riskfactors for mental health problems in 4-5-year-old children: Australian population study. Acad Pediatr 2010;10:41-7
32. Hudson CG. Socioeconomic status and mental illness: tests of the social causation and selection hypotheses. Am J Orthopsychiatry 2005;75:3-18
33. Ibrahim AK, Kelly SJ, Glazebrook C. Socioeconomic status and the risk of depression among UK higher education students. Soc Psychiatry Psychiatr Epidemiol 2013;48:1491-501